The study, published in Circulation: Arrhythmia and Electrophysiology, included data from more than 1,600 patients who presented at the ED with shortness of breath. 

As the COVID-19 pandemic continues, researchers have been forced to put important projects on hold—and it’s unclear when things will return to normal.

The original software first received FDA clearance back in 2018. This updated version, Caption Health has said, is easier for clinicians to use. 

Such testing typically makes the most sense when patients have a confirmed diagnosis of an inherited cardiovascular disease or an abnormality has already been identified.

A new commentary in Circulation: Heart Failure offers a first-hand account of how one facility embraced telehealth and faced the pandemic head-on.

Stress cardiomyopathy—often referred to as broken heart syndrome—was up significantly in March and April 2020.

preCARDIA announced that its catheter-based system for acutely decompensated heart failure has received the FDA’s breakthrough device designation.

Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

The study's authors emphasized the importance of interventions such as patient communication and education. 

With the disease becoming more and more common in the United States, researchers have been hard at work determining the best possible treatment options.

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

The algorithm, developed as part of a collaboration with Mayo Clinic, received Breakthrough Device designation back in December 2019.